Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Porter 2022 Abstract Bioblast

From Bioblast
Karavyraki M, Gnaiger E, Porter RK (2022) A comparison of bioenergetics in human tongue pre-cancerous dysplastic oral keratinocytes and squamous cancer cells. Bioblast 2022: BEC Inaugural Conference.

Link: Bioblast 2022: BEC Inaugural Conference

Karavyraki Marilena, Gnaiger Erich, Porter Richard K (2022)

Event: Bioblast 2022

In an endeavour to understand the metabolic phenotype behind metastasis from oral squamous cell carcinomas, we characterised the bioenergetic profile of a human tongue derived cancer cell line (SCC-4 cells) and compared this profile to a pre-cancerous dysplastic oral keratinocyte (DOK) cell line also derived from human tongue. The human SCC-4 cancer cells had greater mitochondrial abundance but lower mitochondrial oxygen consumption rates than DOK cells. The lower oxygen consumption rate in SCC-4 cells can be partially explained by lower NADH-related enzymatic activity when compared to pre-cancerous DOK cells. In addition, SCC-4 cells have greater extracellular acidification rate (an index of glycolytic flux) when compared to DOK cells. In addition, treatment with recombinant human IL-6 (rhIL-6), known to drive anoikis resistance in SCC-4 cells but not DOK cells, impairs oxygen consumption in SCC-4 but not DOK cells, without affecting mitochondrial abundance. We conclude that SCC-4 cells have a less oxidative phenotype compared to DOK cells and that IL-6 attenuates mitochondrial function in SCC-4 cells while increasing glycolytic flux.

β€’ Keywords: Oral Squamous Cancer Cells, Mitochondria, Interleukin 6, Dysplastic oral keratinocytes, Oxygen consumption β€’ Bioblast editor: Plangger M


Labels:







Affiliations and support

Marilena Karavyraki(1), Erich Gnaiger(2), Richard K. Porter(1)
  1. School of Biochemistry, Trinity Biomedical Science Institute, Trinity College Dublin, Ireland.
  2. Oroboros Instruments, Innsbruck, Austria
Acknowledgements: Marie Curie Grant TRACT 721906 H2020-MCSA-ITN 2016; COST Action CA15203 (2016-2021): MitoEAGLE.